Watch out... J&J buys into lucrative market

Johnson & Johnson is buying Texas-based ophthalmology biotech Ollin Biosciences in a deal worth up to about US$3.3 billion (A$4.9 billion).

To see the whole article, log in or create an account.

Simon Webster